Comparison of the Pharmacokinetics of Glipizide and Glibenclamide in Man

Overview

Journal Eur J Clin Pharmacol

Specialty Pharmacology

Date 1975 Jan 1

PMID 823030

Citations 20

Authors

L Balant

J Fabre

G R ZAHND

Affiliations

Soon will be listed here.

Abstract

Four subjects received 5 mg 14C-glipizide orally, 3 subjects 1 mg intravenously and 2 subjects 5 mg 14C-glibenclamide orally. Plasma levels of radioactivity, and urinary and faecal excretion were measured. For both drugs the disappearance of radioactivity from plasma followed complex kinetics and the apparent half-lives increased steadily with time. The two sulfonylureas were extensively metabolized and were excreted in the urine as hydroxylated or conjugated metabolites. The effects of both drugs on blood glucose and immunoreactive insulin were comparable. The findings are compared with other published results.

Citing Articles

Pharmacoepidemiologic and in vitro evaluation of potential drug-drug interactions of sulfonylureas with fibrates and statins.

Schelleman H, Han X, Brensinger C, Quinney S, Bilker W, Flockhart D Br J Clin Pharmacol. 2014; 78(3):639-48.

PMID: 24548191 PMC: 4243914. DOI: 10.1111/bcp.12353.

The effects of CYP2C9 and CYP2C19 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of glipizide in Chinese subjects.

Tan B, Zhang Y, Chen X, Zhao X, Li G, Zhong D Eur J Clin Pharmacol. 2009; 66(2):145-51.

PMID: 19847408 DOI: 10.1007/s00228-009-0736-2.

Identification of the major human hepatic and placental enzymes responsible for the biotransformation of glyburide.

Zharikova O, Fokina V, Nanovskaya T, Hill R, Mattison D, Hankins G Biochem Pharmacol. 2009; 78(12):1483-90.

PMID: 19679108 PMC: 3982398. DOI: 10.1016/j.bcp.2009.08.003.

Computational models to assign biopharmaceutics drug disposition classification from molecular structure.

Khandelwal A, Bahadduri P, Chang C, Polli J, Swaan P, Ekins S Pharm Res. 2007; 24(12):2249-62.

PMID: 17846869 DOI: 10.1007/s11095-007-9435-9.

Lack of pharmacokinetic interaction for ISIS 113715, a 2'-0-methoxyethyl modified antisense oligonucleotide targeting protein tyrosine phosphatase 1B messenger RNA, with oral antidiabetic compounds metformin, glipizide or rosiglitazone.

Geary R, Bradley J, Watanabe T, Kwon Y, Wedel M, van Lier J Clin Pharmacokinet. 2006; 45(8):789-801.

PMID: 16884318 DOI: 10.2165/00003088-200645080-00003.

References

Rupp W, Christ O, Heptner W . [Resorption, excretion and metabolism after intravenous and oral administration of HB 419-14C in man]. Arzneimittelforschung. 1969; 19(8):Suppl:1428-34. View

Schmidt H, PETRIDES P . [Glucose and HB 419-concentration in blood as well as HB 419-excretion in urine after single oral application of HB 419-14C]. Arzneimittelforschung. 1969; 19(8):Suppl:1422-8. View

DOLUISIO J, DITTERT L . Influence of repetitive dosing of tetracyclines on biologic half-life in serum. Clin Pharmacol Ther. 1969; 10(5):690-701. DOI: 10.1002/cpt1969105690. View

Gibaldi M . Pharmacokinetic aspects of drug metabolism. Ann N Y Acad Sci. 1971; 179:19-31. DOI: 10.1111/j.1749-6632.1971.tb46888.x. View

Hales C, Randle P . Immunoassay of insulin with insulin-antibody precipitate. Biochem J. 1963; 88:137-46. PMC: 1203862. DOI: 10.1042/bj0880137. View

Rupp W, Christ O, Fulberth W . [Studies on the bioavailability of glibenclamide]. Arzneimittelforschung. 1972; 22(2):471-3. View

Fuccella L, Tamassia V, VALZELLI G . Metabolism and kinetics of the hypoglycemic agent glipizide in man--comparison with glibenclamide. J Clin Pharmacol New Drugs. 1973; 13(2):68-75. DOI: 10.1002/j.1552-4604.1973.tb00255.x. View

Fabre J, Kunz J, VIRIEUX C, Laurencet J, PITTON J . [The behavior of doxycycline in man]. Chemotherapia (Basel). 1968; 13:Suppl:23-40. View

ZENDER R . [An automatic micro-method for the quantitative analysis of aldohexoses in biological fluids by o-toluidine]. Clin Chim Acta. 1963; 8:351-8. DOI: 10.1016/0009-8981(63)90071-8. View

10.

Schulz E, Koch K, Schmidt F . [Potentiation of the hypoglycemic effect of sulfonylurea derivatives by drugs. II. Pharmacokinetics and metabolism of glibenclamide (HB 419) in presence of phenylbutazone]. Eur J Clin Pharmacol. 1971; 4(1):32-7. DOI: 10.1007/BF00568896. View

11.

Schmidt H, SCHOOG M, SCHWEER K, Winkler E . Pharmacokinetics and pharmacodynamics as well as metabolism following orally and intravenously administered C14-glipizide, a new antidiabetic. Diabetologia. 1973; :320-30. DOI: 10.1007/BF01218442. View

12.

Anderson J, Stephenson R, Tomlinson R, Weinberg A . Studies with 14C-labelled glibenclaide. Postgrad Med J. 1970; :Suppl:42-5. View

13.

Ambrogi V, ARTINI D, Fuccella L, Goldaniga G, Orsini G, RONCHI R . [Pharmacokinetics and metabolism of N-(4-( -(5-methylpyrazine-2-carboxyamido)-ethyl)-benzensulfonyl)-N'cyclohexylurea (K 4024) in experimental animals and in man]. Boll Chim Farm. 1972; 111(4):251-64. View

14.

Balant L, Zahnd G, Gorgia A, Schwarz R, Fabre J . Pharmacokinetics of glipizide in man: influence of renal insufficiency. Diabetologia. 1973; :331-8. DOI: 10.1007/BF01218443. View

15.

Heptner W, Kellner H, Christ O, Weihrauch D . [Metabolism of HB 419 in animals]. Arzneimittelforschung. 1969; 19(8):Suppl:1400-4. View